BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Rev Clin Immunol 2020;16:1019-28. [PMID: 32954893 DOI: 10.1080/1744666X.2021.1826311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Cingolani L, Barberio B, Zingone F, Ferronato A, Bertani L, Costa F, Bodini G, Demarzo MG, Melatti P, Gubbiotti A, Massimi D, Casadei C, D'Incà R, Savarino EV. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. Sci Rep 2021;11:10368. [PMID: 33990652 DOI: 10.1038/s41598-021-89790-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Gentili M, Hidalgo-Garcia L, Vezza T, Ricci E, Migliorati G, Rodriguez-Nogales A, Riccardi C, Galvez J, Ronchetti S. A recombinant glucocorticoid-induced leucine zipper protein ameliorates symptoms of dextran sulfate sodium-induced colitis by improving intestinal permeability. FASEB J 2021;35:e21950. [PMID: 34613638 DOI: 10.1096/fj.202100778RRRR] [Reference Citation Analysis]
3 Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lönnfors S, Hossne RS, Peyrin-Biroulet L, Queiroz NSF. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. Therap Adv Gastroenterol 2021;14:17562848211013249. [PMID: 34046083 DOI: 10.1177/17562848211013249] [Reference Citation Analysis]
4 Najeeb H, Yasmin F, Surani S. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World J Clin Cases 2022; 10(14): 4327-4333 [DOI: 10.12998/wjcc.v10.i14.4327] [Reference Citation Analysis]